Clinical Trials Logo

Migraine Disorders clinical trials

View clinical trials related to Migraine Disorders.

Filter by:

NCT ID: NCT05509400 Recruiting - Migraine Clinical Trials

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Start date: October 18, 2022
Phase: Phase 4
Study type: Interventional

This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).

NCT ID: NCT05503082 Recruiting - Headache, Migraine Clinical Trials

Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

UNION
Start date: September 6, 2022
Phase: Phase 4
Study type: Interventional

This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.

NCT ID: NCT05472675 Recruiting - Vestibular Migraine Clinical Trials

Local Sensory Nerve Block in the Treatment of Vestibular Migraine

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

There is no standard approach to the treatment of vestibular migraine. Agents used in the treatment of migraine are frequently used. In treating migraine, local anesthetic agents, nerve-blocking methods, and botulinum toxin local injection is commonly applied, and successful results are obtained. Adapting the nerve-blocking method used in the treatment of migraine to the treatment of vestibular migraine is the purpose of the study.

NCT ID: NCT05468801 Recruiting - Migraine Clinical Trials

Efficacy of Individualized Homeopathic Remedies on Migraine: a Randomized, Triple-blind, Placebo Controlled Study.

HOMEOMIG
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Migraine, a chronic and often lifelong neurological disorder, is the second leading cause of years lived with disability worldwide. To reduce this global burden, concerted efforts are needed to implement and improve migraine health-care policies. Several observational studies showed significant improvement of different headaches types with homeopathy. The purpose of this study is the assessment of the efficacy of Individualized Homeopathic Remedies (specific remedies for each patient) versus Conventional pharmacological treatment in patients with migraine.

NCT ID: NCT05458817 Recruiting - Migraine Clinical Trials

Digital-technology Based Interventions on Treatment of Migraine.

Migrevention
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The main aim of the research: To develop an interdisciplinary treatment platform based on digital technology and test the operation and effectiveness of digital interventions in comparison with conventional multidisciplinary treatment or treatment standards (incl. Paper diary, nurse counseling, physiotherapy, cognitive-behavioral therapy).

NCT ID: NCT05454826 Recruiting - Migraine Clinical Trials

Investigation of the Effect of Cold Application in Migraine

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Migraine is a headache that is paroxysmal and can last for hours, sometimes even days due to untreated or ineffective treatment is usually unilateral, throbbing, severe enough to prevent the person's daily life activities, and increases with head movements. It is a chronic disorder characterized by recurrent moderate and severe headaches, mostly associated with a few symptoms in the autonomic nervous system. Migraine consists of recurrent headache attacks accompanied by neurological, gastrointestinal, and autonomic symptoms. Migraine is the most common chronic headache in epidemiological studies. Studies have shown that migraine affects 12% of the general population. The aim of migraine treatment is to reduce the frequency, duration, and severity of migraine attacks, to reduce the losses caused by migraine, and increase the quality of life. In the treatment of migraine, non-pharmacological treatment is as important as pharmacological treatment. Some individuals prefer drug-free treatment methods because of the side effects drugs. In recent years, as the mechanisms of headaches have been better understood, significant developments have been made in treatment methods. Different physiotherapy and rehabilitation methods have been used for treatment. There are studies in which cold application is used in migraine patients, but a study evaluating the effectiveness of cold application has not been found in the literature. The systemic effects of cold have two main purposes: to maintain the current body temperature and to produce energy to raise the fallen body temperature. Knowing both the local and systemic effects of cold guides its use in treatment. The aim of this study was to diagnose migraine. To investigate the effectiveness of cold application applied in addition to relaxation exercises in individuals.

NCT ID: NCT05452239 Recruiting - Migraine Clinical Trials

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Start date: July 1, 2022
Phase: Phase 4
Study type: Interventional

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.

NCT ID: NCT05449145 Recruiting - Episodic Migraine Clinical Trials

The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

First, the aims of this study are to explore the effect of vitamin D versus placebo in the prevention of episodic migraine. Second, we would like to compare and evaluate the effect of vitamin D plus omega-3 fatty acids versus placebo plus omega-3 fatty acids in terms of migraine frequency, symptom severity, and associated complications.

NCT ID: NCT05418218 Recruiting - Fibromyalgia Clinical Trials

International Headache Registry Study

IHRS
Start date: July 12, 2021
Phase:
Study type: Observational [Patient Registry]

In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.

NCT ID: NCT05416476 Recruiting - Clinical trials for Migraine Without Aura

Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine

ATEM
Start date: October 30, 2023
Phase: Phase 3
Study type: Interventional

In this study,288 adult migraine patients aged 18-65 years (diagnosed with migraine without aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate the efficacy, safety and tolerability of Anisodine Hydrobromide in preventing migraine attacks in episodic migraine in adults.